US › Healthcare

Pluri Inc. (PLUR)

US · Healthcare · Biotechnology

$1.56-0.95%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$167,000

Revenue YoY

-60.9%

Net profit

$-6.2M

Profit YoY

-0.4%

EPS

$-0.65

EPS estimate

$-0.74

Net margin

-3,695.8%

EPS came in at -0.65 against a street estimate of -0.74 — a beat of 12.2%.

Key statistics

Market cap

$17.0M

Forward P/E

3.6

P/B

306.56

Book value

$-1.78

EPS (TTM)

$-2.90

52-week high

$5.68

52-week low

$1.45

50-day MA

$2.07

200-day MA

$3.11

Beta

0.68

Analyst view

Analysts rate Pluri Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

46.57%

Institutions

12.55%

Largest institutional holders

Fund	Stake
Renaissance Technologies Corp	0.18%
Morgan Stanley - Brokerage Accounts	0.03%
EverSource Wealth Advisors, LLC	0.02%
Citigroup Inc	0.01%
SIMA Wealth Partners, LLC	0.00%
Wells Fargo & Co	0.00%
Royal Bank of Canada	0.00%
JPMorgan Chase & Co	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pluri Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.